Lake Medical Imaging Scans First Patient in National Alzheimer’s Research Study, “Imaging Dementia – Evidence for Amyloid Scanning” (IDEAS)
Landmark Study Assessing Value of PET Scans in Diagnosing Alzheimer’s Disease and Dementia to Inform Medicare Coverage of Brain Amyloid Imaging
The Villages, March 10, 2016 – Lake Medical Imaging of The Villages, Florida has scanned its first patient into the nationwide “Imaging Dementia – Evidence for Amyloid Scanning” (IDEAS) trial. The two-year trial is designed to evaluate the clinical impact of positron emission tomography (PET) scanning of beta-amyloid deposits in the diagnosis of patients who are being evaluated for Alzheimer’s disease and other causes of cognitive decline.
The IDEAS trial, led by the Alzheimer’s Association and managed by the American College of Radiology (ACR) and American College of Radiology Imaging Network (ACRIN), will enroll a total of 18,488 Medicare beneficiaries age 65 and older who meet specific Appropriate Use Criteria (AUC) from roughly 200 sites throughout the United States. The study protocol received approval with requirements by the Centers for Medicare & Medicaid Services (CMS). Participating providers will be reimbursed for the PET scans under the CMS Coverage with Evidence Development (CED) policy that requires research study participation as a condition of Medicare payment.
“We are excited to be a participant in the IDEAS study. Lake Medical Imaging has always been at the frontier in advanced imaging and our inclusion in this landmark study is a testament to our quality, expertise, and excellence. Results garnered from this study will help shape how imaging can and will be used in the spectrum of Alzheimer’s Disease management and treatment and hopefully will make access to these important imaging studies more available to these patients who need and can benefit from the information gained by the results.” – Anton Serafini, MD, ABR, ABNM of Lake Medical Imaging
Lake Medical Imaging, in partnership with Central Florida Health Alliance, is a full-service diagnostic imaging practice encompassing 23 board certified Radiologists and five state-of-the-art imaging centers in Central Florida.
The purpose of the IDEAS trial is to assess the impact of amyloid PET imaging on the management of patients as well as on major medical outcomes such as hospital admissions and emergency room visits by enrolled patients over a 12-month period, compared to a matched cohort of patients not enrolled in the study.
If you are interested in participating in this clinical trial, talk with your neurologist.